JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 21, 2004; DOI: 10.1124/jpet.104.067751


0022-3565/04/3103-1152-1160$20.00
JPET 310:1152-1160, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.067751v1
310/3/1152    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oz, M.
Right arrow Articles by Lupica, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oz, M.
Right arrow Articles by Lupica, C. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TETRAHYDROCANNABINOL

NEUROPHARMACOLOGY

Differential Effects of Endogenous and Synthetic Cannabinoids on {alpha}7-Nicotinic Acetylcholine Receptor-Mediated Responses in Xenopus Oocytes

Murat Oz, Li Zhang, Arippa Ravindran, Marisela Morales, and Carl R. Lupica

National Institute on Drug Abuse, National Institutes of Health/Department of Health and Human Services, Intramural Research Program, Cellular Neurobiology Branch (M.O., C.R.L.), Behavioral Neurobiology Branch (M.M.), and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health/Department of Health and Human Services, Laboratory of Molecular and Cellular Neurobiology, Bethesda, Maryland (L.Z., A.R.)

The effects of endogenous and synthetic cannabinoid receptor agonists, including 2-arachidonoylglycerol (2-AG), R-methanandamide, WIN55,212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], and CP 55,940 [1{alpha},2{beta}-(R)-5{alpha}]-(-)-5-(1,1-dimethyl)-2-[5-hydroxy-2-(3-hydroxypropyl) cyclohexyl-phenol], and the psychoactive constituent of marijuana, {Delta}9-tetrahydrocannabinol ({Delta}9-THC), on the function of homomeric {alpha}7-nicotinic acetylcholine (nACh) receptors expressed in Xenopus oocytes was investigated using the two-electrode voltage-clamp technique. The endogenous cannabinoid receptor ligands 2-AG and the metabolically stable analog of anandamide (arachidonylethanolamide), R-methanandamide, reversibly inhibited currents evoked with ACh (100 µM) in a concentration-dependent manner (IC50 values of 168 and 183 nM, respectively). In contrast, the synthetic cannabinoid receptor agonists CP 55,940, WIN55,212-2, and the phytochemical {Delta}9-THC did not alter {alpha}7-nACh receptor function. The inhibition of {alpha}7-mediated currents by 2-AG was found to be non-competitive and voltage-independent. Additional experiments using endocannabinoid metabolites suggested that arachidonic acid, but not ethanolamine or glycerol, could also inhibit the {alpha}7-nACh receptor function. Whereas the effects of arachidonic acid were also noncompetitive and voltage-independent, its potency was much lower than 2-AG and anandamide. Results of studies with chimeric {alpha}7-nACh-5-hydroxytryptamine (5-HT)3 receptors comprised of the amino-terminal domain of the {alpha}7-nACh receptor and the transmembrane and carboxyl-terminal domains of 5-HT3 receptors indicated that the site of interaction of the endocannabinoids with the {alpha}7-nAChR was not located on the N-terminal region of the receptor. These data indicate that cannabinoid receptor ligands that are produced in situ potently inhibit {alpha}7-nACh receptor function, whereas the synthetic cannabinoid ligands, and {Delta}9-THC, are without effect, or are relatively ineffective at inhibiting these receptors.


Received February 27, 2004; accepted April 13, 2004.

Address correspondence to: Dr. Murat Oz, National Institute on Drug Abuse/Intramural Research Program, Cellular Neurobiology Branch, 5500 Nathan Shock Dr., Baltimore, MD 21224. E-mail: moz{at}intra.nida.nih.gov




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
U. Baranowska, M. Gothert, R. Rudz, and B. Malinowska
Methanandamide Allosterically Inhibits in Vivo the Function of Peripheral Nicotinic Acetylcholine Receptors Containing the {alpha}7-Subunit
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 912 - 919.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. E. Spivak, C. R. Lupica, and M. Oz
The Endocannabinoid Anandamide Inhibits the Function of {alpha}4beta2 Nicotinic Acetylcholine Receptors
Mol. Pharmacol., October 1, 2007; 72(4): 1024 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
H. Schuel and L. J. Burkman
A Tale of Two Cells: Endocannabinoid-Signaling Regulates Functions of Neurons and Sperm
Biol Reprod, December 1, 2005; 73(6): 1078 - 1086.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Oz, S. N. Jackson, A. S. Woods, M. Morales, and L. Zhang
Additive Effects of Endogenous Cannabinoid Anandamide and Ethanol on {alpha}7-Nicotinic Acetylcholine Receptor-Mediated Responses in Xenopus Oocytes
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1272 - 1280.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.